Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Bayer

ClinicalTrials.gov Identifier:

NCT01271712

First received: December 17, 2010

Last updated: November 24, 2014

Last verified: November 2014

History of Changes

Results First Received: May 24, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Gastrointestinal Stromal Tumors
Interventions:	Drug: Regorafenib (Stivarga, BAY73-4506) Drug: Placebo Drug: Best supportive care

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 240 participants with metastatic and/or unresectable GIST whose disease had progressed despite prior treatments with at least imatinib and sunitinib were screened; 199 were randomized. Patients must have shown objective disease progression or intolerance to imatinib, as well as disease progression while on sunitinib treatment.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were randomized in a 2:1 ratio to receive either regorafenib (133 patients) or placebo (66 patients). Randomization was stratified according 3rd vs. 4th line of therapy (at least 50% of patients were to be 3rd line), and geographical region (Asia vs.rest of world).

Reporting Groups

	Description
Regorafenib (Stivarga, BAY73-4506)	Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Placebo First, Then Option of Open Label Regorafenib Treatment	Double blind phase: participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks. Open Label phase: participants on placebo who switched to Regorafenib, received Regorafenib 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.

Participant Flow for 4 periods

Period 1: Double Blind Treatment

	Regorafenib (Stivarga, BAY73-4506)	Placebo First, Then Option of Open Label Regorafenib Treatment
STARTED	133	66
Participants Received Treatment	132	66
COMPLETED	41 ^[1]	56 ^[2]
NOT COMPLETED	92	10
Death	2	0
Lack of Efficacy	1	0
Adverse Event	8	4
Progressive disease	21	3
Withdrawal by Subject	4	0
Non compliance with study drug	2	0
Ongoing in double-blind treatment	53	3
receive no study drug	1	0

[1]	41 participants started open-label treatment with regorafenib
[2]	56 participants started open-label treatment with regorafenib

Period 2: Open Label Treatment

	Regorafenib (Stivarga, BAY73-4506)	Placebo First, Then Option of Open Label Regorafenib Treatment
STARTED	41	56
Participants Received Treatment	41	56
COMPLETED	0	0
NOT COMPLETED	41	56
Death	1	1
Withdrawal by Subject	0	5
Physician Decision	2	0
Adverse Event	2	4
Progressive disease	12	13
Ongoing with open-label treatment	24	33

Period 3: Safety Follow-up

	Regorafenib (Stivarga, BAY73-4506)	Placebo First, Then Option of Open Label Regorafenib Treatment
STARTED	36 ^[1]	7 ^[1]
COMPLETED	27	4
NOT COMPLETED	9	3
Death	4	2
Withdrawal by Subject	1	1
Protocol Violation	1	0
Ongoing with open-label treatment	3	0

[1]	All participants who discontinued study drug entered 30-day Safety Follow-up

Period 4: Survival Follow-up

	Regorafenib (Stivarga, BAY73-4506)	Placebo First, Then Option of Open Label Regorafenib Treatment
STARTED	27 ^[1]	4 ^[1]
COMPLETED	0	0
NOT COMPLETED	27	4
Death	13	3
Ongoing with open-label treatment	14	1

[1]	All participants entered Survival Follow-up 30 days after discontinuation of study drug

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Regorafenib (Stivarga, BAY73-4506)	Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Placebo	Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Total	Total of all reporting groups

Baseline Measures

	Regorafenib (Stivarga, BAY73-4506)	Placebo	Total
Number of Participants [units: participants]	133	66	199
Age [units: Years] Mean ± Standard Deviation	58.2 ± 12.5	58.1 ± 13.9	58.2 ± 12.9
Gender [units: Participants]
Female	48	24	72
Male	85	42	127
ECOG Performance Status (PS)] ^[1] [units: Participants]
PS 0	73	37	110
PS 1	60	29	89
PS 2	0	0	0
Missing	0	0	0
Prior anti-cancer drug group ^[2] [units: Participants]
3rd line	74	39	113
4th line and beyond	59	27	86

[1]	ECOG = Eastern cooperative oncology group PS levels are 0 (Fully active, able to carry on all pre-disease performance), 1 (ambulatory and able to carry out work of a light or sedentary), 2 (Ambulatory and capable of all selfcare but unable to carry out any work activities), 3 (Capable of only limited selfcare, confined to bed or chair more than 50% of awake time), 4 (Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair) and 5 (death).
[2]	3rd line: 3rd in sequence of multiple therapies: imatinib (1st); sunitinib (2nd). 4th line and beyond: 4th in sequence of multiple therapies: imatinib (1st); sunitinib (2nd); other (3rd).

[1]

ECOG = Eastern cooperative oncology group PS levels are 0 (Fully active, able to carry on all pre-disease performance), 1 (ambulatory and able to carry out work of a light or sedentary), 2 (Ambulatory and capable of all selfcare but unable to carry out any work activities), 3 (Capable of only limited selfcare, confined to bed or chair more than 50% of awake time), 4 (Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair) and 5 (death).

[2]

3rd line: 3rd in sequence of multiple therapies: imatinib (1st); sunitinib (2nd). 4th line and beyond: 4th in sequence of multiple therapies: imatinib (1st); sunitinib (2nd); other (3rd).

Outcome Measures

Show All Outcome Measures

1. Primary:

Progression-free Survival [ Time Frame: From randomization of the first subject until approximately 144 progression-free survival events had occurred (study duration approximately one year) ]

Show Outcome Measure 1

2. Secondary:

Overall Survival [ Time Frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately one year ]

Show Outcome Measure 2

3. Secondary:

Time to Progression (TTP) [ Time Frame: From randomization of the first subject until until date of database cutoff (26 Jan 2012); study duration approximately 1 year ]

Show Outcome Measure 3

4. Secondary:

Tumor Response [ Time Frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year ]

Show Outcome Measure 4

5. Secondary:

Objective Response Rate [ Time Frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year. ]

Show Outcome Measure 5

6. Secondary:

Disease Control Rate (DCR) [ Time Frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year ]

Show Outcome Measure 6

7. Secondary:

Duration of Response (DOR) [ Time Frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year ]

Show Outcome Measure 7

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	From randomization of the first subject until date of database cutoff (26 Jan 2012).
Additional Description	Acronyms used: International Normalized Ratio (INR).

Reporting Groups

	Description
Regorafenib (Double Blind Only)	Regorafenib (Double Blind study phase only): Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Placebo ( Double Blind Only)	Placebo (Double Blind study phase only): Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Regorafenib, Open Label Only (Regorafenib Continued)	Continue Regorafenib (Open Label study phase only): Participants continue to receive Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Placebo, Open Label Only (Switch to Regorafenib)	Switch to Regorafenib (Open Label study phase only): Participants switched to Open label Regorafenib treatment from Placebo. Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks

Serious Adverse Events

	Regorafenib (Double Blind Only)	Placebo ( Double Blind Only)	Regorafenib, Open Label Only (Regorafenib Continued)	Placebo, Open Label Only (Switch to Regorafenib)
Total, serious adverse events
# participants affected / at risk	38/132 (28.79%)	14/66 (21.21%)	9/41 (21.95%)	20/56 (35.71%)
Blood and lymphatic system disorders
Anemia ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Cardiac disorders
Acute coronary syndrome ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Cardiac arrest ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Cardiac disorders - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Ear and labyrinth disorders
Vertigo ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Gastrointestinal disorders
Abdominal pain ^{* 1}
# participants affected / at risk	5/132 (3.79%)	1/66 (1.52%)	0/41 (0.00%)	1/56 (1.79%)
Ascites ^{* 1}
# participants affected / at risk	3/132 (2.27%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Colonic fistula ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Colonic obstruction ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Colonic perforation ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Constipation ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Diarrhea ^{* 1}
# participants affected / at risk	2/132 (1.52%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Gastric hemorrhage ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Intra-abdominal hemorrhage ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Ileus ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Lower gastrointestinal hemorrhage ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Nausea ^{* 1}
# participants affected / at risk	1/132 (0.76%)	1/66 (1.52%)	0/41 (0.00%)	1/56 (1.79%)
Obstruction gastric ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Gastrointestinal disorders - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Peritoneal necrosis ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Retroperitoneal hemorrhage ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Upper gastrointestinal hemorrhage ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Vomiting ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
General disorders
Death NOS ^{* 1}
# participants affected / at risk	1/132 (0.76%)	2/66 (3.03%)	0/41 (0.00%)	0/56 (0.00%)
Fatigue ^{* 1}
# participants affected / at risk	2/132 (1.52%)	2/66 (3.03%)	0/41 (0.00%)	2/56 (3.57%)
Fever ^{* 1}
# participants affected / at risk	3/132 (2.27%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Malaise ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Multi-organ failure ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Non-cardiac chest pain ^{* 1}
# participants affected / at risk	0/132 (0.00%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
General disorders and administration site conditions - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	1/66 (1.52%)	0/41 (0.00%)	1/56 (1.79%)
Pain ^{* 1}
# participants affected / at risk	1/132 (0.76%)	2/66 (3.03%)	0/41 (0.00%)	1/56 (1.79%)
Hepatobiliary disorders
Bile duct stenosis ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Cholecystitis ^{* 1}
# participants affected / at risk	0/132 (0.00%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Hepatic failure ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Hepatic hemorrhage ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Hepatobiliary disorders - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Portal vein thrombosis ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Infections and infestations
Abdominal infection ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Catheter related infection ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Enterocolitis infectious ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	2/56 (3.57%)
Lung infection ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Infections and infestations - Other ^{* 1}
# participants affected / at risk	2/132 (1.52%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Sepsis ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Upper respiratory infection ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Urinary tract infection ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Wound infection ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Investigations
Alanine aminotransferase increased ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	2/56 (3.57%)
Aspartate aminotransferase increased ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Blood bilirubin increased ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	1/56 (1.79%)
Creatinine increased ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
INR increased ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Neutrophil count decreased ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Investigations - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Platelet count decreased ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Metabolism and nutrition disorders
Acidosis ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Dehydration ^{* 1}
# participants affected / at risk	3/132 (2.27%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Hyperglycemia ^{* 1}
# participants affected / at risk	0/132 (0.00%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Hyperkalemia ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Musculoskeletal and connective tissue disorders
Back pain ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	2/56 (3.57%)
Generalized muscle weakness ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Muscle weakness right-sided ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	2/56 (3.57%)
Nervous system disorders
Hypoglossal nerve disorder ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Nervous system disorders - Other ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Paresthesia ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Reversible posterior leukoencephalopathy syndrome ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Somnolence ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Psychiatric disorders
Confusion ^{* 1}
# participants affected / at risk	0/132 (0.00%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Mania ^{* 1}
# participants affected / at risk	0/132 (0.00%)	1/66 (1.52%)	0/41 (0.00%)	0/56 (0.00%)
Psychiatric disorders - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Renal and urinary disorders
Acute kidney injury ^{* 1}
# participants affected / at risk	2/132 (1.52%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Renal and urinary disorders - Other ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Respiratory, thoracic and mediastinal disorders
Adult respiratory distress syndrome ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	1/41 (2.44%)	0/56 (0.00%)
Dyspnea ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Pneumonitis ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Skin and subcutaneous tissue disorders
Rash maculo-papular ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	0/41 (0.00%)	1/56 (1.79%)
Surgical and medical procedures
Surgical and medical procedures - Other ^{* 1}
# participants affected / at risk	0/132 (0.00%)	0/66 (0.00%)	2/41 (4.88%)	0/56 (0.00%)
Vascular disorders
Hypertension ^{* 1}
# participants affected / at risk	1/132 (0.76%)	0/66 (0.00%)	0/41 (0.00%)	0/56 (0.00%)
Thromboembolic event ^{* 1}
# participants affected / at risk	2/132 (1.52%)	0/66 (0.00%)	1/41 (2.44%)	1/56 (1.79%)

*	Events were collected by non-systematic assessment
1	Term from vocabulary, NCI-CTCAE v.4.0

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Therapeutic Area Head
Organization: BAYER
e-mail: clinical-trials-contact@bayerhealthcare.com

Publications of Results:

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

Publications automatically indexed to this study:

Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15.

Responsible Party:	Bayer
ClinicalTrials.gov Identifier:	NCT01271712 History of Changes
Other Study ID Numbers:	14874, 2009-017957-37
Study First Received:	December 17, 2010
Results First Received:	May 24, 2013
Last Updated:	November 24, 2014
Health Authority:	United States: Food and Drug Administration Austria:AGES-PharmMed LCM Belgium:Agence Fédérale des Médicaments et des Produits de Santé Canada: Health Canada China: Food and Drug Administration Finland: Finnish Medicines Agency France: Agence française de sécurité sanitaire des produits de santé (Afssaps) Germany: Federal Institute for Drugs and Medical Devices Israel: Ministry of Health Italy: Agenzia Italiana del Farmaco Japan: Pharmaceuticals and Medical Devices Agency Netherlands: College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Singapore: Health Sciences Authority South Korea: Korea Food and Drug Administration Spain: Agencia Española de Medicamentos y Productos Sanitarios United Kingdom: Medicines and Healthcare Products Regulatory Agency

To Top